This clinical trial is focused on studying the effects of a treatment on patients who have undergone a liver transplantation and are at risk of developing Acute Kidney Injury (AKI). The treatment being tested involves the use of a medication called REVERPLEG, which contains the active substance argipressin. This medication is given as a solution for infusion, meaning it is administered directly into the bloodstream through a vein. The study also involves another medication, NORADRENALINE VIATRIS, which contains noradrenaline tartrate and is also given as a solution for infusion.
The purpose of the study is to see if using a low dose of argipressin during the liver transplant surgery can help reduce the risk of developing AKI afterward. Participants in the study will receive either the argipressin treatment or a placebo during their surgery. The study will monitor the participants for a period after the surgery to observe any effects on kidney function and other health outcomes.
Throughout the study, various health indicators will be tracked, such as the need for blood transfusions, the use of other medications like norepinephrine, and the overall health status of the participants. The study aims to provide valuable information on whether this treatment can improve outcomes for patients undergoing liver transplants and help prevent complications like AKI.
France 
